Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References 1 GROWTH Six in-market growth drivers with multi-bn sales potential and recent launches reinforce our confidence in mid-term growth outlook 6 in-market growth drivers, multi-bn potential Cosentyx® Entresto® zolgensma 33% of IM sales growing 23% (Q3) KISQALIⓇ Kesimpta LEQVIO® Recent launches • SCEMBLIX® All growth rates in constant currencies (cc). 6 Investor Relations | Q3 2022 Results PLUVICTO™ Scemblix and Pluvicto off to a good start NOVARTIS | Reimagining Medicine

View entire presentation